Drug Insights

Is Palforzia approved by the FDA?

27 June 2024
3 min read

Yes, Palforzia is FDA approved. The U.S. Food and Drug Administration (FDA) approved Palforzia on January 31, 2020. This approval marked a significant advancement in the management of peanut allergies, offering a new therapeutic option for those affected.

What is Palforzia?

Palforzia, a peanut allergen extract, is used to help reduce the severity of allergic reactions, including anaphylaxis, when someone accidentally consumes peanuts. However, it is not a treatment for allergic reactions that have already started.

Key Points:

  • Target Group: Palforzia is intended for use in individuals aged 4 years and older who have been diagnosed with a peanut allergy.
  • Special Program: The medication is available only under a special program that requires patients to be registered and understand the associated risks and benefits.

Usage Instructions

Palforzia should be taken exactly as prescribed by a doctor. The initial dose and any dose increases must be administered in a healthcare setting under medical supervision to monitor for any adverse reactions. The medication is taken orally, mixed with a small amount of food like applesauce, yogurt, or pudding, and should not be mixed with liquids.

Dosing Information

Initial Dose Escalation (Ages 4 to 17):

  • Single doses of 0.5 mg, 1 mg, 1.5 mg, 3 mg, and 6 mg taken on a single day under healthcare supervision.
  • Followed by a series of escalating doses administered under similar supervision, each for a duration of two weeks until the maintenance dose is reached.

Maintenance Dose:

  • 300 mg taken orally daily to maintain the effect.

Side Effects

Common side effects of Palforzia include:

  • Itching or burning in the mouth
  • Coughing, wheezing, or trouble breathing
  • Tightness or irritation in the throat
  • Rash, itchy skin
  • Stomach pain, nausea, vomiting

Severe side effects requiring immediate medical attention include:

  • Chest discomfort, wheezing, trouble breathing
  • Swelling of the face, lips, eyes, or tongue
  • Severe stomach pain, vomiting, or diarrhea

Warnings and Precautions

Palforzia can cause severe or life-threatening allergic reactions. Patients must have injectable epinephrine on hand at all times while using Palforzia and should seek emergency medical help if they experience any signs of a severe allergic reaction.

Contraindications:

  • Uncontrolled asthma
  • Problems with the esophagus or digestive tract caused by high eosinophil levels

Conclusion

Palforzia represents an important development in the treatment of peanut allergies, offering a way to mitigate the severity of allergic reactions in case of accidental exposure. Approved by the FDA on January 31, 2020, it provides a structured, monitored approach to desensitization for individuals with peanut allergies, improving their safety and quality of life.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Sun Pharma's GL0034 Shows Promising Weight Loss in Obesity at ADA's 84th Session
Latest Hotspot
3 min read
Sun Pharma's GL0034 Shows Promising Weight Loss in Obesity at ADA's 84th Session
27 June 2024
Sun Pharma's GL0034 (Utreglutide) Showcases Remarkable Weight Loss and Metabolic Improvements in Obesity at ADA's 84th Session.
Read →
Is Trijardy XR approved by the FDA?
Drug Insights
3 min read
Is Trijardy XR approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Trijardy XR on January 27, 2020, for the treatment of type 2 diabetes in adults.
Read →
Takeda Unveils Promising Phase 2b Mezagitamab Data for Primary Immune Thrombocytopenia Treatment
Latest Hotspot
3 min read
Takeda Unveils Promising Phase 2b Mezagitamab Data for Primary Immune Thrombocytopenia Treatment
27 June 2024
Takeda Reveals New Data from Phase 2b Study of Mezagitamab, Showing Potential to Innovate Primary Immune Thrombocytopenia Treatment.
Read →
Is Tazemetostat approved by the FDA?
Drug Insights
3 min read
Is Tazemetostat approved by the FDA?
27 June 2024
The U.S. Food and Drug Administration (FDA) approved Tazemetostat on January 23, 2020, for the treatment of specific types of advanced cancers, specifically epithelioid sarcoma and follicular lymphoma.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.